JP2005528374A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528374A5
JP2005528374A5 JP2003581743A JP2003581743A JP2005528374A5 JP 2005528374 A5 JP2005528374 A5 JP 2005528374A5 JP 2003581743 A JP2003581743 A JP 2003581743A JP 2003581743 A JP2003581743 A JP 2003581743A JP 2005528374 A5 JP2005528374 A5 JP 2005528374A5
Authority
JP
Japan
Prior art keywords
alkyl
carbon atoms
group
amino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003581743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003434 external-priority patent/WO2003084503A2/en
Publication of JP2005528374A publication Critical patent/JP2005528374A/ja
Publication of JP2005528374A5 publication Critical patent/JP2005528374A5/ja
Pending legal-status Critical Current

Links

JP2003581743A 2002-04-05 2003-04-02 粘液分泌過多の治療方法 Pending JP2005528374A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007699 2002-04-05
PCT/EP2003/003434 WO2003084503A2 (en) 2002-04-05 2003-04-02 P38 kinase inhibitors for treating mucus hypersecretion_

Publications (2)

Publication Number Publication Date
JP2005528374A JP2005528374A (ja) 2005-09-22
JP2005528374A5 true JP2005528374A5 (https=) 2006-06-01

Family

ID=28685842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003581743A Pending JP2005528374A (ja) 2002-04-05 2003-04-02 粘液分泌過多の治療方法

Country Status (14)

Country Link
EP (1) EP1494645A2 (https=)
JP (1) JP2005528374A (https=)
KR (1) KR20040101398A (https=)
CN (1) CN1658834A (https=)
AU (1) AU2003224025A1 (https=)
BR (1) BR0309009A (https=)
CA (1) CA2479520A1 (https=)
IL (1) IL163737A0 (https=)
MX (1) MXPA04009605A (https=)
NZ (1) NZ536278A (https=)
PL (1) PL372963A1 (https=)
RU (1) RU2004132847A (https=)
WO (1) WO2003084503A2 (https=)
ZA (1) ZA200406910B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101529A1 (ja) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006137421A1 (ja) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 局所投与剤
FR2903774B1 (fr) * 2006-07-17 2008-09-05 Renault Sas Procede de validation d'un diagnostic de fontionnement d'un dispositif.
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
JP2012504591A (ja) 2008-10-02 2012-02-23 レスピバート・リミテツド p38MAPキナーゼ阻害剤
MX2011006219A (es) 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ATE278674T1 (de) * 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
JP2003500403A (ja) * 1999-05-21 2003-01-07 サイオス,インコーポレーテッド p38キナーゼのインヒビターとしてのインドール型誘導体
KR20080028516A (ko) * 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Jnk억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
BR0014041A (pt) * 1999-09-17 2003-07-15 Smithkline Beecham Corp Utilização de csaids em infecção por rinovìrus
WO2002022605A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004511542A (ja) * 2000-10-19 2004-04-15 スミスクライン・ビーチャム・コーポレイション 煙の吸入の治療のためのp38阻害剤の使用
WO2002083642A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2003041644A2 (en) * 2001-11-09 2003-05-22 Scios Inc. Method to treat cystic fibrosis

Similar Documents

Publication Publication Date Title
RU2004133034A (ru) Новые фармацевтические композиции на основе антихолинергических средств и ингибиторов киназы р38
JP2005529098A5 (https=)
JP2002539198A5 (https=)
JP2004536845A5 (https=)
JP2003514808A5 (https=)
JP2005528374A5 (https=)
CA2352524A1 (en) Aromatic heterocyclic compounds as antiinflammatory agents
JP2005518447A5 (https=)
YU88491A (sh) Amidi izoksazol-4-karboksilne kiseline i amidi hidroksialkiliden-cijanosirćetne kiseline i postupak za dobijanje farmaceutskih preparata koji sadrže ta jedinjenja
CA2511970A1 (en) Urea derivatives useful in the treatment of heart failure
JP2008525502A5 (https=)
JP2005503400A5 (https=)
US20040110755A1 (en) Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
RU2004132847A (ru) Способ лечения гиперсекреции слизи
WO2023001028A1 (zh) 杂芳-3-哌啶二酮类化合物及其应用
JP2020527575A5 (https=)
JP2005538066A5 (https=)
WO2009059030A1 (en) Pyrazole derivatives as kinase inhibitors
EP1545514A1 (en) Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
US20030220336A1 (en) Method of treating mucus hypersecretion
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
DE60310730T2 (de) Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
RU2527561C2 (ru) Ингибиторы протеинфосфатазы-1 и их применение
RU2021102256A (ru) Производные хиназолина биарилэфирного типа
JPWO2014007065A1 (ja) 固形医薬錠剤およびその製造方法